First Tracks Biotherapeutics (TRAX) - Total Liabilities
Based on the latest financial reports, First Tracks Biotherapeutics (TRAX) has total liabilities worth $14.34 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See TRAX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
First Tracks Biotherapeutics - Total Liabilities Trend (2023–2025)
This chart illustrates how First Tracks Biotherapeutics's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of First Tracks Biotherapeutics to evaluate the company's liquid asset resilience ratio.
First Tracks Biotherapeutics Competitors by Total Liabilities
The table below lists competitors of First Tracks Biotherapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lindsay Corporation
NYSE:LNN
|
USA | $322.55 Million |
|
Yibin Tianyuan Group Co Ltd
SHE:002386
|
China | CN¥11.64 Billion |
|
Xiamen Wanli Stone Stock Co Ltd
SHE:002785
|
China | CN¥634.07 Million |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
Taiwan | NT$5.07 Billion |
|
SeAH Bestee
KO:001430
|
Korea | ₩2.05 Trillion |
|
Hanza AB
ST:HANZA
|
Sweden | Skr5.14 Billion |
|
Trupanion Inc
NASDAQ:TRUP
|
USA | $521.14 Million |
|
Wuxi Dk Electronic Materials Co Ltd
SHE:300842
|
China | CN¥10.63 Billion |
Liability Composition Analysis (2023–2025)
This chart breaks down First Tracks Biotherapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TRAX current and non-current assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how First Tracks Biotherapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for First Tracks Biotherapeutics (2023–2025)
The table below shows the annual total liabilities of First Tracks Biotherapeutics from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $43.05 Million | -14.40% |
| 2024-12-31 | $50.30 Million | +46.80% |
| 2023-12-31 | $34.26 Million | -- |
About First Tracks Biotherapeutics
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in bo… Read more